BeiGene (BGNE) Stock Forecast & Price Target

$190.62 +0.32 (+0.17%)

(As of 02:03 PM ET)

BeiGene - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 7 Analyst Ratings

Sell
0

Hold
2

Buy
5

Based on 7 Wall Street analysts who have issued ratings for BeiGene in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 2 have given a hold rating, and 5 have given a buy rating for BGNE.

Consensus Price Target

$247.07
29.61% Upside

According to the 7 analysts' twelve-month price targets for BeiGene, the average price target is $247.07. The highest price target for BGNE is $345.00, while the lowest price target for BGNE is $152.50. The average price target represents a forecasted upside of 29.61% from the current price of $190.62.

Get the Latest News and Ratings for BGNE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BeiGene and its competitors.

BGNE Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$247.07	$246.21	$248.61	$278.08
Forecasted Upside	29.61% Upside	15.70% Upside	25.46% Upside	51.99% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BeiGene Stock vs. The Competition

Type	BeiGene	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	30.48% Upside	24,797.33% Upside	6.96% Upside
News Sentiment Rating	Positive News See Recent BGNE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$254.00 ➝ $260.00	+32.21%
10/22/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $235.00	+7.12%
9/18/2024	JMP Securities 2 of 5 stars	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$288.00	+45.82%
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$269.00 ➝ $288.00	+57.06%
7/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$180.00 ➝ $152.50	+5.82%
3/27/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$196.00 ➝ $161.00	+4.67%
Crypto’s next big bull run? (Ad) Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up … And one special coin could do even better.
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$350.00 ➝ $345.00	+98.62%
9/12/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+25.82%
9/11/2023	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+23.78%
8/29/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$321.00 ➝ $319.00	+50.44%
8/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$287.00	+49.22%
6/30/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
2/28/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$213.00 ➝ $262.00	+21.28%
1/20/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$236.00 ➝ $300.00	+9.29%
1/11/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$308.00	+20.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:47 PM ET.

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 20, 2024. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BeiGene
Bull Case

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

BeiGene, Ltd. reported a significant revenue increase of 56.1% year-over-year, reaching $929.20 million for the latest quarter, indicating strong growth potential and demand for its oncology medicines.
The company beat analysts' earnings per share (EPS) estimates by a substantial margin, reporting ($1.15) compared to the consensus of ($2.27), which reflects better-than-expected financial performance.
Recent analyst ratings have been positive, with several firms upgrading their price targets, including Citigroup raising its target to $288.00, suggesting confidence in the company's future performance.
As of the latest trading session, BeiGene, Ltd. shares are priced at $188.15, which may present a buying opportunity for investors looking for growth in the biotech sector.
Institutional ownership stands at 48.55%, indicating strong confidence from large investors, which can be a positive signal for retail investors considering the stock.

BeiGene
Bear Case

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

Despite the revenue growth, BeiGene, Ltd. has a negative net margin of 16.91%, which suggests that the company is currently not profitable and may face challenges in achieving sustainable profitability.
The company has a negative return on equity of 14.93%, indicating that it is not generating a positive return for its shareholders, which could deter potential investors.
Insider selling has been notable, with CEO John Oyler selling 6,175 shares recently, which may raise concerns about the company's future prospects and insider confidence.
Analysts project a negative EPS of -5 for the current year, which could signal ongoing financial difficulties and a lack of profitability in the near term.
The stock has experienced volatility, trading down 2.7% recently, which may indicate market uncertainty and could be a risk factor for investors.

BGNE Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $247.07, with a high forecast of $345.00 and a low forecast of $152.50.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares.
: According to analysts, BeiGene's stock has a predicted upside of 29.61% based on their 12-month stock forecasts.
: BeiGene has been rated by research analysts at JMP Securities, JPMorgan Chase & Co., and TD Cowen in the past 90 days.
: Analysts like BeiGene less than other "medical" companies. The consensus rating score for BeiGene is 2.71 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BGNE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

One coin could soar when Trump’s elected … (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Click here to find out more about what could be Trump and JD Vance’s favorite coin.

This page (NASDAQ:BGNE) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeiGene (BGNE) Stock Forecast & Price Target